Search Results - "Suh, Koung Jin"

Refine Results
  1. 1

    Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody by Suh, Koung Jin, Kim, Se Hyun, Kim, Yu Jung, Kim, Miso, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog, Lee, Jong Seok

    Published in Cancer Immunology, Immunotherapy (01-03-2018)
    “…We investigated inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) that may predict the response to anti-PD-1 (programmed cell death protein…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study by Kim, Jin Won, Lee, Kyung-Hun, Kim, Ji-Won, Suh, Koung Jin, Nam, Ah-Rong, Bang, Ju-Hee, Bang, Yung-Jue, Oh, Do-Youn

    Published in British journal of cancer (13-08-2019)
    “…Background A phase Ib study of binimetinib and capecitabine for gemcitabine-pretreated biliary tract cancer (BTC) patients was conducted. Methods Binimetinib…”
    Get full text
    Journal Article
  5. 5

    Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients by Heo, Ja Yoon, Yoo, Shin Hye, Suh, Koung Jin, Kim, Se Hyun, Kim, Yu Jung, Ock, Chan-Young, Kim, Miso, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog, Lee, Jong Seok

    Published in Scientific reports (28-01-2021)
    “…Although immune checkpoint inhibitors (ICIs) can induce durable responses in non-small-cell lung cancer (NSCLC) patients, a significant proportion of…”
    Get full text
    Journal Article
  6. 6

    Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer by Kim, Kyeonghui, Kim, Hyemin, Shin, Inkyung, Noh, Seung-Jae, Kim, Jeong Yeon, Suh, Koung Jin, Kim, Yoo-Na, Lee, Jung-Yun, Cho, Dae-Yeon, Kim, Se Hyun, Kim, Jee Hyun, Lee, Se-Hoon, Choi, Jung Kyoon

    Published in Scientific reports (18-12-2023)
    “…Genomic hypomethylation has recently been identified as a determinant of therapeutic responses to immune checkpoint blockade (ICB). However, it remains unclear…”
    Get full text
    Journal Article
  7. 7

    Performance of clinician prediction of survival in oncology outpatients with advanced cancer by Kim, Yu Jung, Yoon, Seok Joon, Suh, Sang-Yeon, Hiratsuka, Yusuke, Kang, Beodeul, Lee, Si Won, Ahn, Hong-Yup, Suh, Koung Jin, Kim, Ji-Won, Kim, Se Hyun, Kim, Jin Won, Lee, Keun-Wook, Kim, Jee Hyun, Lee, Jong Seok

    Published in PloS one (21-04-2022)
    “…We aimed to investigate the performance of clinician prediction of survival (CPS) and the association between CPS and the prognostic confidence of clinicians…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study by Kang, Minsu, Suh, Koung Jin, Kim, Ji-Won, Byun, Ja Min, Kim, Jin Won, Lee, Ji Yun, Lee, Jeong-Ok, Bang, Soo-Mee, Kim, Yu Jung, Kim, Se Hyun, Kim, Jee Hyun, Lee, Jong Seok, Lee, Keun-Wook

    Published in PloS one (18-01-2022)
    “…Splanchnic vein thrombosis (SpVT) in solid tumors has not been well investigated. Therefore, the treatment guidelines for SpVT are not well established. We…”
    Get full text
    Journal Article
  11. 11

    Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study by Choi, In Sil, Choi, Mihong, Lee, Ju Hyun, Kim, Jee Hyun, Suh, Koung Jin, Lee, Ji Yun, Kang, Beodeul, Kim, Ji-Won, Kim, Se-Hyun, Kim, Jin Won, Lee, Jeong-Ok, Kim, Yu Jung, Bang, Soo-Mee, Lee, Jong Seok, Lee, Keun-Wook

    Published in PloS one (07-06-2018)
    “…There is limited data on third-line chemotherapy in patients with metastatic gastric cancer (MGC). This study was conducted to assess third-line treatment…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15

    The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer by Kim, Jin Won, Lee, Kyung‐Hun, Kim, Ji‐Won, Suh, Koung Jin, Nam, Ah‐Rong, Bang, Ju‐Hee, Jin, Mei Hua, Oh, Kyoung‐Seok, Kim, Jae‐Min, Kim, Tae‐Yong, Oh, Do‐Youn

    Published in Liver international (01-02-2021)
    “…Background This study aimed to evaluate the association between soluble TGF‐β (sTGF‐β) and soluble PD‐L1 (sPDL1), the dynamics of sTGF‐β during treatment and…”
    Get full text
    Journal Article
  16. 16

    A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study by Choi, In Sil, Kim, Jee Hyun, Lee, Ju Hyun, Suh, Koung Jin, Lee, Ji Yun, Kim, Ji-Won, Kim, Se-Hyun, Kim, Jin Won, Lee, Jeong-Ok, Kim, Yu Jung, Bang, Soo-Mee, Lee, Jong Seok, Lee, Keun-Wook

    Published in PloS one (22-10-2018)
    “…The survival benefit of second-line chemotherapy in patients with metastatic gastric cancer (MGC) has recently been established. We conducted a nationwide…”
    Get full text
    Journal Article
  17. 17

    EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release by Suh, Koung Jin, Sung, Ji Hea, Kim, Jin Won, Han, Song-Hee, Lee, Hye Seung, Min, Ahrum, Kang, Mi Hyun, Kim, Ji Eun, Kim, Ji-Won, Kim, Se Hyun, Lee, Jeong-Ok, Kim, Yu Jung, Lee, Keun-Wook, Kim, Jee Hyun, Bang, Soo-Mee, Im, Seock-Ah, Lee, Jong Seok

    Published in Oncotarget (08-09-2017)
    “…Characteristics of tumor microenvironment have been suggested as predictive markers of anti-EGFR or anti-HER2 treatment response. However, the effect of…”
    Get full text
    Journal Article
  18. 18

    Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials by Suh, Koung Jin, Lee, Ji Yun, Shin, Dong-Yeop, Koh, Youngil, Bang, Soo-Mee, Yoon, Sung-Soo, Park, Seonyang, Kim, Inho, Lee, Jeong-Ok

    Published in International journal of hematology (01-08-2017)
    “…We analyzed adverse events (AEs) in 201 chronic phase CML patients treated with nilotinib ( n  = 120) or dasatinib ( n  = 81) as first- or second-line therapy…”
    Get full text
    Journal Article
  19. 19

    Prognostic effects of abnormal DNA damage response protein expression in breast cancer by Suh, Koung Jin, Ryu, Han Suk, Lee, Kyung-Hun, Kim, Hyojin, Min, Ahrum, Kim, Tae-Yong, Yang, Yaewon, Lee, Han-Byoel, Moon, Hyeong-Gon, Han, Sae-Won, Oh, Do-Youn, Han, Wonshik, Park, In Ae, Noh, Dong-Young, Im, Seock-Ah

    Published in Breast cancer research and treatment (01-05-2019)
    “…Purpose We aimed to explore the expression of DNA damage response machinery proteins and their integrated prognostic value in different subgroups of breast…”
    Get full text
    Journal Article
  20. 20